Melanotan I
Melanotan I is a linear alpha-MSH analog run off-label almost exclusively for cosmetic tanning and sun protection, yet the captured community corpus is thin: just five reports, all positive but held at only medium confidence. Those five anecdotes offer no reliable guidance on dose, timing, or cycling, and specific protocol details remain entirely undocumented in community discussion. The central tradeoff is that the off-label evidence base is substantially thinner than the online discourse suggests, with most exploratory indications still lacking posted results.
Research Evidence
Evidence shape
Melanotan I has high-tier evidence specifically for erythropoietic protoporphyria, with the strongest trials among the six studies targeting that indication. The full map lists eighteen distinct conditions, yet posted results appear in only one area, supported by seven blinded trials with results and five distinct sponsors. The remaining sixteen indications are thin or exploratory, plus one animal-only track, and twelve are single-trial entries, leaving most of the map without replication.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Melanotan I is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Timing
- unspecified
- Cycle
- unspecified
20 completed trials identified; trial dosing not reliably extracted from registry data.
No structured protocol details captured for this tier yet.
- Frequency
- unspecified
- Timing
- unspecified
- Route
- unknown
- Cycle
- unspecified
Community reports mention use for skin tanning and pigmentation, however, specific dosing details regarding amounts, frequency, or route were not available in the reported cases.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
- • Hypersensitivity: Serious hypersensitivity reactions, including anaphylaxis, have been reported. If a serious hypersensitivity reaction occurs, initiate appropriate therapy and remove the SCENESSE implant if needed. The patient should not receive any further…
- • Skin Monitoring: May induce darkening of pre-existing nevi and ephelides due to its pharmacological effect. A full body skin examination (twice yearly) is recommended to monitor pre-existing nevi and new skin pigmentary lesions .
- • CONTRAINDICATIONS SCENESSE is contraindicated in
- • patients with a history of severe hypersensitivity reaction to afamelanotide or to any of the excipients in SCENESSE . Known hypersensitivity to afamelanotide or to any of the excipients in SCENESSE .
Peptide feedback
0 forum repliesLive community discussion for Melanotan I, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.